Home - Quirem Medical

Company statement on the coronavirus outbreak The global community is dealing with the severe consequences of the coronavirus disease (COVID-19) pandemic. Our hearts go out to everyone around the world who is being affected by the coronavirus, either directly or indirectly. In these challenging times we remain fully committed to doing everything possible to continue to serve our customers and patients around the world in the best possible way.

You are unique, and your treatment should be too.

To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.

LifeHAck

Introducing Q-Suite™

Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.

LEARN MORE

Events

Meet us in Munich at CIRSE 2020

The Quirem team will attend CIRSE in Munich from 12-16 September 2020.

Visit the CIRSE 2020 website

SIRT in three steps

Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:

1. SELECT

Select only those patients that are likely to benefit from SIRT. Use QuiremScout^®, a safe dose of holmium microspheres, to evaluate the biodistribution of particles prior to therapy in your patients.

2. TREAT

Treat with QuiremSpheres^®, the next-generation microspheres, indicated for treatment of unresectable liver tumors. Click here to learn what value QuiremSpheres® can bring to your clinic.

3. VERIFY

Use our software package Q-Suite^TM to determine SIRT succes right after the procedure, by evaluating the absorbed dose in the lesions and normal liver tissue

News and events

News

Lancet Oncology reports safety and efficacy of Holmium-166 SIRT after PRRT

Terumo Europe N.V. and Quirem Medical B.V are proud to share the latest key publication regarding holmium-166 (QuiremSpheres®) Selective Internal Radiation Therapy (SIRT). On 27 February 2020, the UMC Utrecht published their latest results in

February 27, 2020

News

Thirona, Quirem, and Radboud university medical center launch the Radiology of the Future project

Radiology of the Future revolves around smart and fast image processing. Achieving this requires research and entrepreneurship. This is the reason that Thirona, Quirem, and Radboud university medical center work together in the Radiology of

February 20, 2020

News

QuiremSpheres® procedure broadcasted live during the annual LINC congress in Leipzig

29 January 2020 – LEIPZIG On Wednesday 29th of January 2020 a QuiremSpheres® live case was performed to treat a patient suffering from intrahepatic cholangiocellular carcinoma in the left liver lobe. The procedure – which

January 29, 2020

What our customers say

“With QuiremSpheres we see the majority of our patients responding much quicker than what we are used to seeing with Y-90. The lesions are already shrinking just 45 days post-procedure. In fact, two of our patients originally deemed to be non-surgical candidates had a resection and a transplant, respectively, after radioembolization with QuiremSpheres^®.”

“The short halftime of holmium-166 in QuiremSpheres^® results in a high initial dose rate. Therefore, we expect to see an improved radiobiological effect.”

"QuiremScout^® enables us to evaluate the safety and efficacy profile of SIRT, prior to the therapeutic procedure. We can now select and treat only those patients that are likely to benefit from SIRT."

“QuiremSpheres^® gives us the confidence we need to start individualizing treatments.”

Zutphenseweg 55

7418AH Deventer

The Netherlands

Telephone: +31 85 0404170

E-mail: info@quirem.com